• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

何时、何种情况以及如何换药：骨髓纤维化中JAK抑制剂的应用指南

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.

作者信息

O'Sullivan Jennifer, Omerdeen Imran, Psaila Bethan

机构信息

MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

出版信息

Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19929.

DOI:10.1111/bjh.19929
PMID:39604140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7617962/
Abstract

Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi-naïve and for those who have previously been treated with a JAKi.

摘要

为初治的骨髓纤维化患者以及既往接受过JAK抑制剂（JAKi）治疗的患者选择JAKi治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98cd/7617962/5d25a4137d20/EMS206884-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98cd/7617962/5d25a4137d20/EMS206884-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98cd/7617962/5d25a4137d20/EMS206884-f001.jpg

相似文献

1
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.何时、何种情况以及如何换药：骨髓纤维化中JAK抑制剂的应用指南
Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19929.
2
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.莫洛替尼与费德拉替尼治疗骨髓纤维化患者安全性的间接治疗比较
Future Oncol. 2025 Jul;21(16):2077-2087. doi: 10.1080/14796694.2025.2511564. Epub 2025 Jun 6.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
4
What are the therapeutic options for previously treated myelofibrosis?对于既往接受过治疗的骨髓纤维化，有哪些治疗选择？
Expert Rev Hematol. 2025 Apr-May;18(5):387-398. doi: 10.1080/17474086.2024.2423367. Epub 2024 Nov 4.
5
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.莫洛替尼与帕西替尼治疗骨髓纤维化患者安全性及贫血转归的间接治疗比较
Future Oncol. 2025 Jul;21(16):2067-2075. doi: 10.1080/14796694.2025.2511562. Epub 2025 Jun 6.
6
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
7
How I individualize selection of JAK inhibitors for patients with myelofibrosis.我如何为骨髓纤维化患者个体化选择JAK抑制剂。
Blood. 2025 Apr 17;145(16):1724-1737. doi: 10.1182/blood.2023022415.
8
Janus kinase/signal transducer and activator of transcription signalling pathway is involved in the immune mechanism of bullous pemphigoid.Janus激酶/信号转导子和转录激活子信号通路参与大疱性类天疱疮的免疫机制。
Br J Dermatol. 2025 Aug 18;193(3):521-531. doi: 10.1093/bjd/ljaf219.
9
JAK inhibitors for the management of rheumatic diseases when antiphospholipid syndrome co-exists: case-based safety considerations.抗磷脂综合征并存时用于治疗风湿性疾病的JAK抑制剂：基于病例的安全性考量
Lupus. 2025 Jul;34(8):852-857. doi: 10.1177/09612033251344180. Epub 2025 May 20.
10
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.用于治疗骨髓纤维化的Janus激酶1和Janus激酶2抑制剂。
Cochrane Database Syst Rev. 2015 Apr 10;2015(4):CD010298. doi: 10.1002/14651858.CD010298.pub2.

本文引用的文献

1
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.非格司亭用于既往接受过鲁索替尼治疗的骨髓纤维化患者的疗效和安全性（FREEDOM2）：一项多中心、开放标签、随机、对照、3期试验的结果
Lancet Haematol. 2024 Oct;11(10):e729-e740. doi: 10.1016/S2352-3026(24)00212-6. Epub 2024 Sep 9.
2
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.莫米松替比 versus 持续芦可替尼或 JAK 抑制剂治疗经验的骨髓纤维化伴贫血患者的最佳可用治疗：SIMPLIFY-2 的亚组分析。
Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11.
3
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations.骨髓纤维化中 JAK 抑制作用的不断发展：单药治疗和联合治疗。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):667-675. doi: 10.1182/hematology.2023000452.
4
The management of myelofibrosis: A British Society for Haematology Guideline.骨髓纤维化的管理：英国血液学学会指南
Br J Haematol. 2024 Jan;204(1):136-150. doi: 10.1111/bjh.19186. Epub 2023 Dec 1.
5
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.Momelotinib用于血小板减少的骨髓纤维化患者：三项随机3期试验的事后分析
Hemasphere. 2023 Oct 27;7(11):e963. doi: 10.1097/HS9.0000000000000963. eCollection 2023 Nov.
6
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.既往接受鲁索替尼治疗失败后的骨髓纤维化患者应用 Fedratinib 的真实世界应用：患者特征、治疗模式和临床结局。
Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):122-132. doi: 10.1016/j.clml.2023.09.008. Epub 2023 Sep 29.
7
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.从芦可替尼立即转换为莫洛替尼治疗的骨髓纤维化患者的临床结局
Haematologica. 2024 Feb 1;109(2):676-681. doi: 10.3324/haematol.2023.283106.
8
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.莫洛替尼与达那唑治疗有症状的贫血和骨髓纤维化患者的疗效对比（MOMENTUM）：一项国际、双盲、随机、对照3期研究的结果
Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0.
9
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.SIMPLIFY-1 和 SIMPLIFY-2 期临床试验中，芦可替尼治疗骨髓纤维化患者的总生存情况。
Leukemia. 2022 Sep;36(9):2261-2268. doi: 10.1038/s41375-022-01637-7. Epub 2022 Jul 22.
10
Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story.芦可替尼真的能延长骨髓纤维化患者的生存期吗？这是个没完没了的故事。
Blood Adv. 2022 Apr 12;6(7):2331-2333. doi: 10.1182/bloodadvances.2022007230.